New drug trial targets specific cancer gene mutation
NCT ID NCT05639751
Summary
This first-in-human study tested a new drug called PRT3789, both alone and combined with the chemotherapy docetaxel, in people with advanced solid tumors that have a specific SMARCA4 gene mutation. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help control the cancer. The study enrolled 135 adults whose cancer had progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Medical Group Oncology Research at Celebration
Celebration, Florida, 34747, United States
-
Centre Leon Berard
Lyon, 69373, France
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital Universitario HM Sanchinarro
Madrid, Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Leids Universitair Medisch Centrum
Leiden, 2333 ZA, Netherlands
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic, Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
National Cancer Centre Singapore
Singapore, Singapore, 168583, Singapore
-
National University Hospital
Singapore, Singapore, 119074, Singapore
-
New York Presbyterian Hospital - Columbia University Medical Center
New York, New York, 10032, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oncopole Claudius Regaud IUCT ONCOPOLE
Toulouse, 31059, France
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
START Barcelona - HM Nou Delfos
Barcelona, Barcelona, 08023, Spain
-
START MADRID - FJD Hospital Universitario Fundacion Jimenez Diaz
Madrid, Madrid, 28040, Spain
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, 06511, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, 90404, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California, Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
lnstitut Bergonie Centre Regionale de Lutte Contre le cancer, Service Oncologie-Medicale
Bordeaux, 33000, France
-
lnstitut Paoli Calmettes
Marseille, 13009, France
Conditions
Explore the condition pages connected to this study.